Truist Financial Has Lowered Expectations for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price objective dropped by Truist Financial from $59.00 to $50.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 60.31% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. TD Cowen initiated coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. Finally, KeyCorp started coverage on shares of Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $63.67.

Astrana Health Stock Up 3.0 %

Shares of NASDAQ ASTH opened at $31.19 on Monday. The business’s fifty day simple moving average is $39.07 and its 200-day simple moving average is $46.97. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 12-month low of $29.08 and a 12-month high of $63.20. The stock has a market cap of $1.75 billion, a P/E ratio of 23.99, a PEG ratio of 1.80 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the prior year, the company posted $0.47 earnings per share. As a group, equities analysts predict that Astrana Health will post 1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. acquired a new position in shares of Astrana Health in the third quarter worth $13,383,000. Franklin Resources Inc. purchased a new position in Astrana Health in the 3rd quarter valued at about $1,187,000. Hohimer Wealth Management LLC purchased a new stake in Astrana Health during the 3rd quarter worth approximately $312,000. Geode Capital Management LLC bought a new position in Astrana Health during the 3rd quarter valued at $58,995,000. Finally, Barclays PLC acquired a new position in shares of Astrana Health in the 3rd quarter worth approximately $4,457,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.